Trevi Therapeutics (TRVI) Total Debt (2020 - 2023)

Trevi Therapeutics' Total Debt history runs 4 years deep, the most recent figure standing at $7.5 million for Q1 2023.

• In Q1 2023, Total Debt fell 46.77% year-over-year to $7.5 million; the TTM figure through Mar 2023 stood at $7.5 million (down 46.77% YoY), while the FY2022 annual figure was $9.2 million, down 36.82% from the prior year.
• Total Debt for Q1 2023 stood at $7.5 million, down from $9.2 million in the prior quarter.
• The five-year high for Total Debt was $14.5 million in Q4 2021, with the low at $7.5 million in Q1 2023.
• The 4-year median for Total Debt is $14.0 million (2020), against an average of $12.6 million.
• The sharpest annual moves came in 2021 and 2023: Total Debt increased 3.84% in 2021, then plunged 46.77% in 2023.
• Trevi Therapeutics' Total Debt stood at $14.0 million in 2020, then climbed by 3.81% to $14.5 million in 2021, then tumbled by 36.82% to $9.2 million in 2022, then dropped by 18.24% to $7.5 million in 2023.
• Business Quant data shows TRVI's Total Debt at $7.5 million in Q1 2023, $9.2 million in Q4 2022, and $10.8 million in Q3 2022.